Healthcare Services

Infectious Disease Therapeutics Market Insights Highlighting Opportunities and Drivers Supporting Growth to 2030

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Infectious Disease Therapeutics Market Between 2026 And 2030?

The infectious disease therapeutics market has experienced robust expansion in recent years. This market is projected to expand from $150.6 billion in 2025 to $160.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this expansion has been driven by factors such as the significant global prevalence of infectious diseases, the extensive application of antibiotics and antivirals, the implementation of government immunization initiatives, the increase in pharmaceutical manufacturing capabilities, and enhanced financial support for infectious disease research.

The infectious disease therapeutics market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $200.87 billion, demonstrating a compound annual growth rate (CAGR) of 5.7%. This growth over the forecast period is attributable to several factors, including heightened rates of antimicrobial resistance, a greater incidence of infectious disease outbreaks, broader global vaccination coverage, an increasing need for new antiviral treatments, and more robust public health preparedness efforts. Key trends anticipated during this period involve an increased emphasis on managing antimicrobial resistance, the expanded creation of broad-spectrum treatments, wider acceptance of combination drug regimens, the development of more rapid-response therapeutics for outbreaks, and enhanced investment in vaccine research and stock accumulation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

What Key Drivers Are Influencing The Growth Of The Infectious Disease Therapeutics Market?

The increasing incidence of infectious diseases is anticipated to stimulate the growth of the infectious disease therapeutics market in the coming period. These diseases are conditions resulting from pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions. The surge in infectious diseases can be attributed to several critical factors including climate change and environmental disruption, antimicrobial resistance, compromised immune systems, heightened interactions with animals, and ecological disturbances. Infectious disease therapeutics are essential for managing infections, diminishing morbidity and mortality, and controlling the dissemination of communicable illnesses within communities and across populations. For instance, in October 2023, the National Health Service (NHS) England, a UK-based government department, reported that during 2022/23, hospitals recorded 147,285 admissions with a primary diagnosis of urinary tract infection (UTI). Patients aged over 65 constituted 56% of these instances, amounting to 82,392 admissions. The 80–84 age group registered the highest volume of admissions, with 17,280 cases. Consequently, the rising prevalence of infectious diseases acts as a driver for the infectious disease therapeutics market.

Which Market Segments Are Examined In The Infectious Disease Therapeutics Market Study?

The infectious disease therapeutics market covered in this report is segmented –

1) By Type: Drugs, Vaccines

2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases

3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users

Subsegments:

1) By Drugs: Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines

What Key Trends Are Influencing The Development Of The Infectious Disease Therapeutics Market?

Leading firms within the infectious disease therapeutics market are increasingly integrating multispecific antibody platforms, including technologies like the multispecific therapeutic antibody reactor (MSTAR), with the aim of boosting effectiveness, extending protective capabilities, and improving their ability to respond to novel viral dangers.

The multispecific therapeutic antibody reactor (MSTAR) represents a sophisticated multispecific antibody technology, which unites multiple distinct binding sites into a singular therapeutic entity, thereby allowing for extensive viral neutralization, concurrent targeting of various epitopes, and quick adjustment to new viral strains.

As an illustration, in September 2023, ModeX Therapeutics Inc, a clinical-stage biopharmaceutical company situated in the US, secured an agreement with the Biomedical Advanced Research and Development Authority to further develop its multispecific antibody candidates. These candidates are intended for treating and preventing viral infectious diseases like COVID 19 and influenza, distinguished by their wide-ranging activity against current viral strains, potential for gene-based delivery via mRNA or DNA vectors, and a multi-binding site structure.

This strategy involving multispecific antibodies enhances patient outcomes by reducing the time required for development, broadening the scope of protection, and simplifying the complexities typically linked with combination biologic therapies.

Who Are The Primary Competitors In The Infectious Disease Therapeutics Market?

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.

Read the full infectious disease therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Infectious Disease Therapeutics Market?

North America was the largest region in the infectious disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Infectious Disease Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Therapeutics Market 2026, By The Business Research Company

Infection Control Global Market Report

https://www.thebusinessresearchcompany.com/report/infection-control-global-market-report

Hospital Acquired Infection Control Global Market Report

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infection-control-global-market-report

Infection Prevention Global Market Report

https://www.thebusinessresearchcompany.com/report/infection-prevention-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795